Royalty Pharma (Royalty Pharma) Interest Expense

: $-187 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Royalty Pharma's interest expense for the three months ended in Dec. 2023 was $ -47 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-187 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Royalty Pharma's Operating Income for the three months ended in Dec. 2023 was $ 613 Mil. Royalty Pharma's Interest Expense for the three months ended in Dec. 2023 was $ -47 Mil. Royalty Pharma's Interest Coverage for the quarter that ended in Dec. 2023 was 12.97. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Royalty Pharma Interest Expense Historical Data

The historical data trend for Royalty Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-268.57

-157.06

-166.14

-187.96

-187.19

Royalty Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-46.96	-46.95	-46.95	-46.03	-47.26

Royalty Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-187 Mil.

Royalty Pharma (NAS:RPRX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Royalty Pharma's Interest Expense for the three months ended in Dec. 2023 was $-47 Mil. Its Operating Income for the three months ended in Dec. 2023 was $613 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $6,135 Mil.

Royalty Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	612.896	/	-47.255
	=	12.97

The higher the ratio, the stronger the company's financial strength is.

Royalty Pharma (Royalty Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RPRX:Mexico RPD:Germany RPD:Germany

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Executives

Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd	10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne	officer: EVP & CFO	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta	director, officer: CEO, Chairman of the Board	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd	officer: EVP, Investments & GC	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani	director, 10 percent owner	C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch	officer: EVP, Research & Investments	C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic	10 percent owner	C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a.	10 percent owner	18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert	director	110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez	director	MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080